1.Plasma D-dimer Can Effectively Predict the Prospective Occurrence of Ascites in Advanced Schistosomiasis Japonica Patients.
Xiaoying WU ; Jianwei REN ; Zulu GAO ; Yun XU ; Huiqun XIE ; Tingfang LI ; Yanhua CHENG ; Fei HU ; Hongyun LIU ; Zhihong GONG ; Jinyi LIANG ; Jia SHEN ; Zhen LIU ; Feng WU ; Xi SUN ; Zhongzheng NIU ; An NING
The Korean Journal of Parasitology 2017;55(2):167-174
China still has more than 30,000 patients of advanced schistosomiasis while new cases being reported consistently. D-dimer is a fibrin degradation product. As ascites being the dominating symptom in advanced schistosomiasis, the present study aimed to explore a prediction model of ascites with D-dimer and other clinical easy-achievable indicators. A case-control study nested in a prospective cohort was conducted in schistosomiasis-endemic area of southern China. A total of 291 patients of advanced schistosomiasis were first investigated in 2013 and further followed in 2014. Information on clinical history, physical examination, and abdominal ultrasonography, including the symptom of ascites was repeatedly collected. Result showed 44 patients having ascites. Most of the patients' ascites were confined in the kidney area with median area of 20 mm². The level of plasma D-dimer and pertinent liver function indicators were measured at the initial investigation in 2013. Compared with those without ascites, cases with ascites had significantly higher levels of D-dimer (0.71±2.44 μg/L vs 0.48±2.12 μg/L, P=0.005), as well ALB (44.5 vs 46.2, g/L) and Type IV collagen (50.04 vs 44.50 μg/L). Receiver operating characteristic curve analyses indicated a moderate predictive value of D-dimer by its own area under curve (AUC) of 0.64 (95% CI: 0.54–0.73) and the cutoff value as 0.81 μg/L. Dichotomized by the cutoff level, D-dimer along with other categorical variables generated a prediction model with AUC of 0.76 (95% CI: 0.68–0.89). Risks of patients with specific characteristics in the prediction model were summarized. Our study suggests that the plasma D-dimer level is a reliable predictor for incident ascites in advanced schistosomiasis japonica patients.
Area Under Curve
;
Ascites*
;
Case-Control Studies
;
China
;
Cohort Studies
;
Collagen Type IV
;
Fibrin
;
Humans
;
Kidney
;
Liver
;
Physical Examination
;
Plasma*
;
Prospective Studies*
;
ROC Curve
;
Schistosoma japonicum
;
Schistosomiasis japonica*
;
Schistosomiasis*
;
Ultrasonography
2.The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus.
Lei LIU ; Zhongzheng XIANG ; Yi LI ; Wei GUO ; Kai YANG ; Jun WANG ; Zhijun SUN ; Guoxin REN ; Jianguo ZHANG ; Moyi SUN ; Wei RAN ; Guilin HUANG ; Zhangui TANG ; Longjiang LI
West China Journal of Stomatology 2022;40(6):619-628
Immune checkpoint inhibitors (ICIs) present significant efficacy in the treatment of malignant tumors, and they have been approved as the first-line of treatment for various cancers. Pembrolizumab monotherapy or combined with chemotherapy has been recommended by domestic and foreign guidelines for the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma. Although ICIs represent a milestone in the treatment of head and neck squamous cell carcinoma, potential problems still need to be addressed, such as the selection of the efficacy predictors for ICIs, the evaluation of the tumor response to ICIs, and the treatment of immune hyperprogression and immune-related adverse events. Therefore, to form a relatively unified understanding of ICIs treatment for head and neck squamous cell carcinoma, we integrated the clinical experience of multi-disciplinary experts of head and neck cancers on the basis of current clinical hot issues and finally developed this consensus.
Humans
;
Squamous Cell Carcinoma of Head and Neck/drug therapy*
;
Immune Checkpoint Inhibitors
;
Consensus
;
Neoplasm Recurrence, Local/pathology*
;
Head and Neck Neoplasms/drug therapy*
3.RGS16 regulated by let-7c-5p promotes glioma progression by activating PI3K-AKT pathway.
Chaochao WANG ; Hao XUE ; Rongrong ZHAO ; Zhongzheng SUN ; Xiao GAO ; Yanhua QI ; Huizhi WANG ; Jianye XU ; Lin DENG ; Gang LI
Frontiers of Medicine 2023;17(1):143-155
Gliomas are the most common central nervous system tumours; they are highly aggressive and have a poor prognosis. RGS16 belongs to the regulator of G-protein signalling (RGS) protein family, which plays an important role in promoting various cancers, such as breast cancer, pancreatic cancer, and colorectal cancer. Moreover, previous studies confirmed that let-7c-5p, a well-known microRNA, can act as a tumour suppressor to regulate the progression of various tumours by inhibiting the expression of its target genes. However, whether RGS16 can promote the progression of glioma and whether it is regulated by miR let-7c-5p are still unknown. Here, we confirmed that RGS16 is upregulated in glioma tissues and that high expression of RGS16 is associated with poor survival. Ectopic deletion of RGS16 significantly suppressed glioma cell proliferation and migration both in vitro and in vivo. Moreover, RGS16 was validated as a direct target gene of miR let-7c-5p. The overexpression of miR let-7c-5p obviously downregulated the expression of RGS16, and knocking down miR let-7c-5p had the opposite effect. Thus, we suggest that the suppression of RGS16 by miR let-7c-5p can promote glioma progression and may serve as a potential prognostic biomarker and therapeutic target in glioma.
Humans
;
Phosphatidylinositol 3-Kinases/metabolism*
;
Proto-Oncogene Proteins c-akt/metabolism*
;
MicroRNAs/metabolism*
;
Glioma/genetics*
;
Genes, Tumor Suppressor
;
Cell Proliferation
;
Gene Expression Regulation, Neoplastic
;
Cell Line, Tumor